FTC Takes "Pay for Delay" Drug Case to U.S. Supreme Court

The Federal Trade Commission asked the US Supreme Court on Thursday to take up its fight against deals between brand-name drug companies and generic firms which they say delay the production of cheaper medicines.

The U.S. solicitor general filed an appeal on behalf of the agency asking the high court to hear the FTC's fight with Solvay, now owned by Abbott Laboratories, and three generic makers.

The companies had made a deal, sometimes called a "reverse payment," that the FTC said meant higher prices for AndroGel, a testosterone cream used by men with low testosterone.

"The anticompetitive potential of reverse-payment agreements -- which are estimated to cost consumers billions of dollars annually -- is sufficiently clear that they should be treated as presumptively unlawful," the FTC said in its court filing.

The case began in 2003, when Solvay, which makes AndroGel, filed a lawsuit accusing generic rivals Watson Pharmaceuticals, Paddock Laboratories and later Par Pharmaceutical of infringing on its patents for the drug.

The companies settled in 2006. Solvay agreed to share some of its AndroGel profits with the generic companies through 2015. In return, they agreed to keep their own versions of AndroGel off the market and to help manufacture and promote the brand-name drug.

The FTC sued both the brand-name and generic companies in 2009, arguing that the deal violated antitrust law. The agency lost in district court and also lost on appeal.

The FTC has fought such deals for more than 10 years, with mixed success. The agency has pushed for legislation to ban the patent settlements or make it easier for the FTC to challenge them.

Telephone calls to the four drug companies seeking comment were not immediately returned.

The Supreme Court case is Federal Trade Commission v. Watson Pharmaceuticals, Inc., No. 12-416.

 

 

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.